Allscripts vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Rebranded to Veradigm Jan 2023; $620-635M revenue expected 2024; 180K+ physician users; 3.6% ambulatory EHR market share; sold hospital business to Harris Computer $700M 2022; Nasdaq suspended Feb 2024
About
Allscripts is a healthcare IT company founded in 1986 in Chicago, historically one of the largest providers of electronic health record and practice management software for physician practices and hospitals in the United States. The company rebranded to Veradigm in January 2023, signaling a strategic pivot from legacy EHR software toward data analytics, life sciences research enablement, and healthcare network intelligence — areas where its 180,000+ physician user base and de-identified patient data assets create differentiated value for pharmaceutical and payer customers.\n\nThe Veradigm platform combines its ambulatory EHR and practice management software with a data and analytics layer that aggregates real-world clinical data for life sciences research, post-market drug surveillance, and population health analytics. Its network of physician practices represents one of the largest ambulatory data footprints in the US, making Veradigm a valuable partner for pharmaceutical companies seeking real-world evidence and patient registries. The company maintains a 3.6% share of the ambulatory EHR market while building out higher-margin analytics and data licensing revenue streams.\n\nVeradigm (formerly Allscripts) targets $620–635M in revenue for 2024, serving 180,000+ physician users across its installed EHR base. The rebrand to Veradigm reflects management's intent to migrate the business model from competitive, commoditizing EHR software toward network and data platform economics. As life sciences companies increase investment in real-world evidence and physicians demand more integrated practice intelligence tools, Veradigm's combination of clinical workflow reach and data network assets gives it a credible platform for this strategic repositioning.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.